Literature DB >> 12084041

Fulminant hepatic failure associated with benzbromarone treatment: a case report.

Makoto Arai, Osamu Yokosuka, Keiichi Fujiwara, Hiroshige Kojima, Tatsuo Kanda, Hiroyuki Hirasawa, Hiromitsu Saisho.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12084041     DOI： 10.1046/j.1440-1746.2002.02692.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN： 0815-9319            Impact factor:   4.029


× No keyword cloud information.
  16 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

Review 3.  The challenges of gout management in the elderly.

Authors:  Lisa K Stamp; Sarah Jordan
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 4.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Autoimmune hepatitis following drug-induced liver injury in an elderly patient.

Authors:  Junichiro Kumagai; Tatsuo Kanda; Shin Yasui; Yuki Haga; Reina Sasaki; Masato Nakamura; Shuang Wu; Shingo Nakamoto; Makoto Arai; Yotaro Iino; Osamu Yokosuka
Journal:  Clin J Gastroenterol       Date:  2016-05-12

6.  Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Authors:  Mattheus K Reinders; Eric N van Roon; Pieternella M Houtman; Jacobus R B J Brouwers; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

Review 7.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

Review 8.  Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

Authors:  John S Bomalaski; Mike A Clark
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 9.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.